Literature DB >> 16373049

Clinical trials: bad combinations or bad designs.

Juan de la Haba-Rodríguez, Auxiliadora Gómez, Enrique Aranda.   

Abstract

Mesh：

Year:  2005        PMID： 16373049     DOI： 10.1007/BF02716591

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  14 in total

1.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

Authors:  H Mouridsen; M Gershanovich; Y Sun; R Pérez-Carrión; C Boni; A Monnier; J Apffelstaedt; R Smith; H P Sleeboom; F Jänicke; A Pluzanska; M Dank; D Becquart; P P Bapsy; E Salminen; R Snyder; M Lassus; J A Verbeek; B Staffler; H A Chaudri-Ross; M Dugan
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.

Authors:  M-L Luoma; L Hakamies-Blomqvist; J Sjöström; A Pluzanska; S Ottoson; H Mouridsen; N-O Bengtsson; J Bergh; P Malmström; V Valvere; L Tennvall; C Blomqvist
Journal:  Eur J Cancer       Date:  2003-07       Impact factor: 9.162

3.  The cross rates of growth of human mammary carcinoma.

Authors:  S Kusama; J S Spratt; W L Donegan; F R Watson; C Cunningham
Journal:  Cancer       Date:  1972-08       Impact factor: 6.860

4.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Authors:  Fairooz F Kabbinavar; Joseph Schulz; Michael McCleod; Taral Patel; John T Hamm; J Randolph Hecht; Robert Mass; Brent Perrou; Betty Nelson; William F Novotny
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

5.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors:  Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

6.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

Authors:  J Bonneterre; B Thürlimann; J F Robertson; M Krzakowski; L Mauriac; P Koralewski; I Vergote; A Webster; M Steinberg; M von Euler
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Prognostic value of performance status and quality-of-life scores during chemotherapy for advanced breast cancer. The Australian New Zealand Breast Cancer Trials Group.

Authors:  A Coates; J Forbes; R J Simes
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

9.  A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

Authors:  Melody A Cobleigh; Virginia K Langmuir; George W Sledge; Kathy D Miller; Latrice Haney; William F Novotny; James D Reimann; Amy Vassel
Journal:  Semin Oncol       Date:  2003-10       Impact factor: 4.929

10.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors:  David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.